Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with HiDAC and Mitoxantrone in AML
NCT02573363Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Oct 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 56 days. Started Oct 2015; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02573363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573363.